Veraxa Biotech Ag logo

Veraxa Biotech Ag(NASDAQ) VRXA

Market Cap$159.55MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2024)-89%
5 YearN/A
1 Year-90%
1 Month-39%
$1.29
+19.44%
+0.21Today
Veraxa Biotech Ag last closing stock price
MetricPriceDate
Last closeUSD 1.082026-10-06
Veraxa Biotech Ag stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-17.56%USD 1.312026-09-29
1 month-38.64%USD 1.762026-09-04
3 month-60.87%USD 2.762026-07-08
Year to date-89.88%USD 10.672025-12-31
1 year-89.68%USD 10.472025-10-06
Since inception-89.17%USD 9.972024-09-30

Veraxa Biotech Ag Financials at a Glance

Market Cap

$159.55MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

$6.74

EPS (TTM)

$0.21

P/E Ratio

5.04

Dividend

$0.00

Beta (Volatility)

0.55 (Low)

Price

$1.29

Volume

458,782.723

Open

$1.16

Previous Close

$1.08

Daily Range

$1.10 - $1.32

52-Week Range

$1.04 - $27.36

Estimated Earnings Date

N/A

VRXA News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Veraxa Biotech Ag

Veraxa Biotech Holding AG is a biotechnology company focused on developing innovative antibody-based therapeutics and antibody-drug conjugates for cancer treatment. Founded in 2021 and based in Heidelberg, Germany, the company leverages a proprietary technology platform for functional antibody screening and bioconjugation.

Products and Services
  • Antibody-drug conjugates (ADCs) for targeted cancer therapy
  • Bispecific antibody formats for enhanced therapeutic efficacy
  • Partnership models for collaborative development from target identification to product creation
Growth Outlook
  • Strong pipeline with several drug candidates in clinical development
  • Increasing demand for targeted cancer therapies in the healthcare market
  • Potential for strategic partnerships to accelerate product development
Financial Highlights
  • Market capitalization of approximately $233 million
  • Stock price range between $1.27 and $27.36 over the past year
  • Low beta of 0.261 indicates lower volatility compared to the market
Veraxa Biotech Holding AG is positioned in a rapidly evolving biotechnology sector, focusing on advanced cancer treatments. The company's innovative approach to antibody-based therapies aims to address significant unmet medical needs. With a robust product pipeline and strategic partnership opportunities, Veraxa is well-placed to capitalize on the growing demand for targeted therapies. The financial metrics indicate a stable market presence, with a relatively low volatility profile, making it an intriguing option for investors interested in the biotechnology field.
AI Generated • Sep 12, 2026

Industry

Biotechnology

Sector

Health Care

Employees

3

CEO

Christoph Antz, PhD

Website

www.voyageracq.com

Headquarters

Heidelberg, ZH 69120, DE

VRXA Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

5.72%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

19.84%

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

$159.55MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

147.73M

Volume

458.78K

Avg. Volume

383.14K

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Veraxa Biotech Ag Performance Analysis

Veraxa Biotech Ag annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Veraxa Biotech Ag annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-12-31USD -0.00N/A
20242024-12-31USD 0.13N/A
20252025-12-31USD 0.28116.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

N/A

N/A

Market Cap

$159.55MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$126.61

N/A

Employees

3

N/A

Net Income

$0.18

+0.1%

EBITDA

-$2.19

+8.3%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$0.03

-92.6%

Total Debt

$0.00

N/A

Accounts Receivable

N/A

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

2.52%

+0.5%

Return on Invested Capital

35.06%

N/A

Free Cash Flow

-$0.15

+0.7%

Operating Cash Flow

-$0.15

+0.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,828.74+0.01%
^DJIDJI
$51,532.64+0.01%
^IXICNASDAQ
$27,658.12+0.01%
BTCBitcoin
$85,726.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SXTCChina Sxt Pharmaceuticals
$5.39+331.20%
BULLWebull
$5.92-18.75%
INTCIntel
$113.26+0.67%
NOKNokia
$10.72-2.28%

Questions About VRXA

What is the current price of Veraxa Biotech Ag?

Veraxa Biotech Ag is trading at $1.32 per share.

What is the 52-week range for Veraxa Biotech Ag?

Over the past 52 weeks, Veraxa Biotech Ag has traded between $1.04 and $27.36.

How much debt does Veraxa Biotech Ag have?

As of the most recent reporting period, Veraxa Biotech Ag reported total debt of $0.00.

How much cash does Veraxa Biotech Ag have on hand?

Veraxa Biotech Ag reported $32.79K in cash and cash equivalents in its most recent financial results.

What is Veraxa Biotech Ag’s dividend yield?

Veraxa Biotech Ag does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services